MDAI vs. NMTC, FEMY, AKLI, IINN, RVP, ICU, LYRA, PYPD, NEPH, and LNSR
Should you be buying Spectral AI stock or one of its competitors? The main competitors of Spectral AI include NeuroOne Medical Technologies (NMTC), Femasys (FEMY), Akili (AKLI), Inspira Technologies Oxy B.H.N. (IINN), Retractable Technologies (RVP), SeaStar Medical (ICU), Lyra Therapeutics (LYRA), PolyPid (PYPD), Nephros (NEPH), and LENSAR (LNSR). These companies are all part of the "surgical & medical instruments" industry.
Spectral AI (NASDAQ:MDAI) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, community ranking, dividends, earnings, risk, analyst recommendations, valuation and institutional ownership.
67.1% of Spectral AI shares are held by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are held by institutional investors. 56.7% of Spectral AI shares are held by company insiders. Comparatively, 7.5% of NeuroOne Medical Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Spectral AI has a net margin of 0.00% compared to NeuroOne Medical Technologies' net margin of -478.41%. Spectral AI's return on equity of 0.00% beat NeuroOne Medical Technologies' return on equity.
Spectral AI currently has a consensus target price of $4.00, suggesting a potential upside of 136.69%. NeuroOne Medical Technologies has a consensus target price of $2.20, suggesting a potential upside of 92.98%. Given Spectral AI's higher probable upside, analysts plainly believe Spectral AI is more favorable than NeuroOne Medical Technologies.
NeuroOne Medical Technologies has lower revenue, but higher earnings than Spectral AI.
In the previous week, Spectral AI had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 7 mentions for Spectral AI and 5 mentions for NeuroOne Medical Technologies. NeuroOne Medical Technologies' average media sentiment score of 0.63 beat Spectral AI's score of 0.61 indicating that NeuroOne Medical Technologies is being referred to more favorably in the news media.
NeuroOne Medical Technologies received 62 more outperform votes than Spectral AI when rated by MarketBeat users. However, 100.00% of users gave Spectral AI an outperform vote while only 71.59% of users gave NeuroOne Medical Technologies an outperform vote.
Spectral AI has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.
Summary
Spectral AI beats NeuroOne Medical Technologies on 9 of the 14 factors compared between the two stocks.
Get Spectral AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spectral AI Competitors List
Related Companies and Tools
